Valeant Pharmaceuticals International today announced it has completed the previously announced acquisition of Salix Pharmaceuticals.
HHS awarded approximately $12 million today to BioCryst Pharmaceuticals of Durham, North...
Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan)...
Recipharm AB and Adroit Science AB have announced the formation of a new strategic collaboration...
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon.
The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.
Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.
AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
There are many nuances that require a more focused approach to risk identification and project management for the “new” manufacturing facilities implementing Single-use Systems (SUS).
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Coronado Biosciences has announced the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology.
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. The transaction is expected to close on 31 March 2015.
Puerto Rico and AbbVie announced today the expansion of one of AbbVie’s existing sites in the island with an estimated investment of $30M. This expansion will add to Puerto Rico’s capabilities as a manufacturing destination for biotechnology and is expected to create up to 100 new jobs over the next two years.
Xcelience has received approval from the Federal Drug Enforcement AdminIstration to develop and manufacture Schedule I controlled substances in their facilities. Schedule I substances are "considered the most dangerous class of drugs," according to the DEA website.
Janssen has announced that a pre-planned interim analysis of the Phase 3 HELIOS study investigating the combination of IMBRUVICA plus bendamustine and rituximab (BR) versus placebo plus BR in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, showed the trial has met its primary endpoint.
Galapagos NV has announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies.
Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion and commissioning of new high containment facilities for potent product manufacture at its Edinburgh, UK site (Macfarlan Smith).
Florida's Governor Rick Scott announced the expansion of Xcelience, an international contract development and manufacturing organization (CDMO) servicing the pharmaceutical and biotechnology industries. Xcelience will expand product development services and manufacturing operations in Tampa, creating 100 new jobs and retaining another 100 jobs. Xcelience will also invest $9M in the region as part of the expansion.
Berry Plastics Group, Inc. and Klöckner Pentaplast Group, announced that the companies recently entered into a marketing alliance to offer innovative form-fill seal packaging solutions, on a global basis to the food, consumer, pharmaceutical, and medical markets.
Google-backed genetic testing company 23andMe is launching its own drug development unit, betting that it can translate its database of customer DNA information into novel medicines.
Particle Sciences, Inc. is expanding its sterile and aseptic manufacturing capacity generally and specifically for nano-milled drug products.
Construction research firm CMD expects starts of industrial construction projects to increase 7.8 percent this year due in large part to reshoring efforts by U.S. manufacturers.
Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for greater regulatory clarity concerning therapeutic interchangeability could hinder market uptake, according to a study recently completed by the Tufts Center for the Study of Drug Development.
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets.
The venture capital arm of the New Jersey consumer products giant officially unveiled its JLABS@South San Francisco campus Monday. The 30,000-square foot incubator will eventually house up to 50 startups.
Blueprint Medicines has announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease.
Catalent Pharma Solutions has announced several expanded capabilities within its European Clinical Supply Services network. The expansions have been implemented in response to increased customer demand for specialty clinical packaging, where the proportion of highly-potent or temperature-sensitive investigational medical products continues to increase.
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies will be rebranded to reflect the new integrated management structure that has been put in place and the broader product and service offerings of the combined organizations.
- Page 1